Regulations.gov document
Patent Term Extension Application for NEXTSTELLIS ® (drospirenone and estetrol…
Other · FDA-2022-E-2185 · posted Sep 9, 2022
Key facts
| Document ID | FDA-2022-E-2185-0002 |
|---|---|
| Title | Patent Term Extension Application for NEXTSTELLIS ® (drospirenone and estetrol tablets).U.S. Patent No. 7,732,43 |
| Document type | Other |
| Subtype | Application |
| Agency | FDA |
| Docket | FDA-2022-E-2185 |
| Posted | Sep 9, 2022 |
| Comment period opens | Sep 9, 2022 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: